The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
Replicate will receive research funding and could potentially receive up to approximately US$550 million
Investment supports Company’s plans to manufacture the vast majority of advanced medicines in the U.S. to meet the needs of patients in the U.S.
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
Inclacumab was generally well tolerated in THRIVE-131
The new facility will enhance AbbVie’s chemical synthesis capacity to support domestic production of current and next-generation neuroscience, immunology, and oncology medicines
Subscribe To Our Newsletter & Stay Updated
